Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Apr

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Long-Term Immunotherapy for Alveolar Soft Part Sarcoma

AMA Data Show Nearly 50 Percent of Surveyed Oncologists Reported Burnout in 2025

Unique Phase I NSCLC Trial Sites Decreasing in United States

Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer